Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance by Du, Peina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals
clinical relevance
Du, Peina; Huang, Peide; Huang, Xuanlin; Li, Xiangchun; Feng, Zhimin; Li, Fengyu; Liang,
Shaoguang; Song, Yongmei; Stenvang, Jan; Brünner, Nils; Yang, Huanming; Ou, Yunwei;








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Du, P., Huang, P., Huang, X., Li, X., Feng, Z., Li, F., ... Li, L. (2017). Comprehensive genomic analysis of
Oesophageal Squamous Cell Carcinoma reveals clinical relevance. Scientific Reports, 7, [15324].
https://doi.org/10.1038/s41598-017-14909-5
Download date: 03. Feb. 2020
1Scientific REPORtS | 7: 15324  | DOI:10.1038/s41598-017-14909-5
www.nature.com/scientificreports
Comprehensive genomic analysis 
of Oesophageal Squamous Cell 
Carcinoma reveals clinical relevance
Peina Du1, Peide Huang1,2, Xuanlin Huang1, Xiangchun Li1,3, Zhimin Feng1, Fengyu Li1, 
Shaoguang Liang1, Yongmei Song4, Jan Stenvang2, Nils Brünner2, Huanming Yang1,5, Yunwei 
Ou6, Qiang Gao1 & Lin Li1,7
Oesophageal carcinoma is the fourth leading cause of cancer-related death in China, and more than 90% 
of these tumours are oesophageal squamous cell carcinoma (ESCC). Although several ESCC genomic 
sequencing studies have identified mutated somatic genes, the number of samples in each study was 
relatively small, and the molecular basis of ESCC has not been fully elucidated. Here, we performed an 
integrated analysis of 490 tumours by combining the genomic data from 7 previous ESCC projects. We 
identified 18 significantly mutated genes (SMGs). PTEN, DCDC1 and CUL3 were first reported as SMGs 
in ESCC. Notably, the AJUBA mutations and mutational signature4 were significantly correlated with 
a poorer survival in patients with ESCC. Hierarchical clustering analysis of the copy number alteration 
(CNA) of cancer gene census (CGC) genes in ESCC patients revealed three subtypes, and subtype3 
exhibited more CNAs and marked for worse prognosis compared with subtype2. Moreover, database 
annotation suggested that two significantly differential CNA genes (PIK3CA and FBXW7) between 
subtype3 and subtype2 may serve as therapeutic drug targets. This study has extended our knowledge 
of the genetic basis of ESCC and shed some light into the clinical relevance, which would help improve 
the therapy and prognosis of ESCC patients.
Oesophageal cancer is one of the most common malignant tumours in the world, and its 5-year survival rate is 
under 20%1. In China, oesophageal cancer is also one of the leading causes of cancer death, following lung, stom-
ach and liver cancer2. There are approximately 478,000 newly diagnosed oesophageal cancer patients and 375,000 
deaths from the disease every year in China2. Recently, large-scale investigations on ESCC have been performed 
in China, focusing on the discovery of new driver mutations that may be closely associated with the development 
of oesophageal cancer. Song et al.3 identified the new oncogene mutant FAM135B, which promoted malignant 
phenotypes in 17 whole genome sequencing (WGS) and 71 whole exome sequencing (WES) cases. Gao et al.4 
discovered EP300 to have tumour suppressor function in 113 WES ESCC cases and to be associated with a poor 
prognosis. However, due to the limited sample size, we were still unclear about the mechanisms of ESCC tumour-
igenesis, especially the contribution of low-frequency mutated genes5. Coupled with the heterogeneity of cancer 
mutations, a comprehensive analysis of oesophageal cancer mutation mechanisms to further the understanding of 
ESCC-related genes will be an important foundation for ESCC diagnosis and treatment. This study combined the 
genomic data obtained in seven previously published studies (Supplementary Tables 1 and 2)3,4,6–10 on squamous 
cell carcinoma to discover genes that are associated with prognosis.
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Results
Somatic mutations in ESCC. We identified a total of 52,964 nonsilent mutations and 16,204 silent muta-
tions in ESCC coding regions, with a median of 97 nonsilent mutations per tumour (Supplementary Tables 3–4). 
We then compared the nonsilent mutations of ESCC to EAC and other cancer types. The somatic mutations were 
highly variable between or within different cancer classes (Supplementary Fig. 1); ESCC displays fewer nonsilent 
mutations per tumour than EAC (median, ESCC: 97; EAC: 117.5) and a higher number than other cancers imme-
diately below lung cancer and melanoma.
Deciphering the mutational Signatures in ESCC. Consistent with previous studies of ESCC, the 
mutational spectrum showed that C:G > T:A transition was the predominant type, followed by C:G > A:T and 
C:G > G:C transversions (Fig. 1A, Supplementary Table 5). To further understand the process of mutation in 
ESCC, a non-negative matrix-factorization method was applied to decipher mutational signatures from 490 
ESCC tumours, and 5 mutational signatures were generated (Fig. 1B). Signature1 was characterized primarily by 
C > T and C > G mutations at TpCpN trinucleotides, and has been confirmed to be associated with the APOBEC 
family of cytidine deaminases, which played an important role in the deaminase activity of single-stranded DNA 
(ssDNA)11,12. Signature2 was characterized by C > T mutations at NpCpG trinucleotides. This mutational pro-
cess has been detected in almost all previous studies of oesophageal cancer13 and is related to the spontaneous 
deamination of 5-methyl-cytosine. Signature3, which is characterized by C > A mutations, was likely caused by 
tobacco mutagens14 and has been observed in many human cancers, including head and neck cancer, liver can-
cer, lung cancer, and oesophageal cancer14. Signature3 was observed in 127 patients, of whom 80 were smokers, 
accounting for 63% of these cases. Signature4 was characterized mainly by C > T mutations and was associated 
with defective DNA mismatch repair. Patients with signature4 exhibited poor survival (Fig. 1C). Signature5 has 
been found in oesophageal cancer7, but the aetiology of this process remains unknown. The comprehensive anal-
ysis of larger sample set enabled us to identify more comprehensive mutational signatures of ESCC and analyse 
the different mechanisms of carcinogenesis. Hierarchical clustering was performed based on the enrichment of 
Figure 1. Mutational signature analysis of ESCC. (A) Lego plots of mutational frequencies in the coding 
regions in ESCC specimens. Base substitutions were classified into six subtypes and each category was 
represented by different colours. Pie charts represent the distribution of the six subtypes. Base substitutions were 
further divided into 96 possible mutation types according to the flanking nucleotides surrounding the mutated 
base. (B) Heatmap for mutational signatures using sample exposures to one signature identified in ESCC 
specimens by the NMF method. Each column represents one individual. Each row represents one signature. 
(C,D) Top: Kaplan-Meier survival curves for signature4 and cluster3 were significantly associated with patient 
survival, p < 0.1 was considered statistically significant. Bottom: Cox proportional hazards model for patients, 
p < 0.05 was considered statistically significant.
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specific mutational signatures, and 3 clusters were identified. Cluster1 was dominated by signature3, Cluster2 was 
dominated by signatures 1 and 5, and Cluster3 was dominated by signature2. The three groups were associated 
with different survival times. Cluster3 exhibited a better prognosis compared with patients in clusters 1 and 2 by 
Kaplan-Meier analysis (p = 0.026, log-rank test) (Fig. 1D).
Significantly mutated genes in ESCC. The MutSigCV method was used to identify SMGs in the 490 
ESCC tumours. Finally, 18 SMGs were identified (Fig. 2, Supplementary Table 6), 15 of which had been pre-
viously reported in ESCC (TP53, AJUBA, CDKN2A, KMT2D(MLL2), ZNF750, FAT1, NOTCH1, NOTCH3, 
PIK3CA, NFE2L2, RB1, KDM6A, FBXW7, CREBBP, and TGFBR2). CUL3, PTEN and DCDC1 were identified 
as novel SMGs in our study. As the most important tumour suppressor, the nonsilent mutation frequency of 
TP53 was 84.90% in 490 tumours, which was consistent with previous reports3,4,7. In our study, the nonsilent 
mutation rate of AJUBA was 3.9%, including two stop-gain and three frame shift mutations in the LIM domain 
(Fig. 3A). Survival analysis revealed that AJUBA was significantly associated with prognosis (p = 0.026, log–rank 
test, Fig. 3B). We also found the expression level of AJUBA was higher in ESCC tumour tissues compared to 
normal samples, and the expression level of AJUBA was lower in AJUBA-mutated tumour samples than in the 
wild-type tumour samples in ESCC cohort (p < 0.001, Student’s t-test, Fig. 3C; p < 0.001, Student’s t-test, Fig. 3D). 
NOTCH1, which encodes a member of the NOTCH family of proteins, has been reported to be an important gene 
in many human cancers, including ESCC. We found that NOTCH1 is significantly correlated with tumour stage 
(Fisher’s exact test, p < 0.001) and lymph node metastasis (Fisher’s exact test, p < 0.001), consistent with previous 
studies8,15.
KDM6A is another SMG in our study (Supplementary Fig. 2A), which had been reported as a driver gene in 
ESCC4.
We identified six mutations in the phosphatase domain (p.A86T, p.R130*, p.R130Q(2), p.F145I, p.Q171*) 
and six mutations in the C2 domain (p.G209A, p.F215C, p.K263*, p.Q245*, p.F257S, p.VL317fs) of the tumour 
repressor PTEN (Supplementary Fig. 2A).
We identified 14 somatic mutations in CUL3 gene, 13 of which were located in the Cullin domain 
(Supplementary Fig. 2A), which provides a scaffold for ubiquitin ligases (E3).
We identified 4 mutations in the ecTbetaR2 domain of the gene TGFBR2, which was also known as transform-
ing growth factor beta receptor 2 ectodomain and transmits signals from the cell surface into the cell. We also 
identified 7 mutations in another important domain, protein tyrosine kinase, which is a key regulator of normal 
cellular processes and has a critical role in the development of many cancers16.
We identified 15 nonsilent mutations in DCDC1 gene, of which 11 were missense mutations and 3 were non-
sense mutations. We also observed a genomic deletion region containing DCDC1 in 31 WGS data sets.
Function classification of SMGs. To further investigate the biological function of cancer-associated genes, 
we classified SMGs into six categories according to previous functional studies. TP53, CDKN2A, NFE2L2, RB1, 
and CUL3 were involved in cell cycle and apoptosis regulation (Supplementary Fig. 3A). The histone modifier 
genes included KDM6A and MLL2. AJUBA, FAT1, FBXW7, NOTCH3 and NOTCH1 were involved in Wnt sig-
nalling and the NOTCH pathway. PIK3CA and PTEN were involved in the PI3 kinase pathway. PIK3CA encodes 
the catalytic subunit of phosphatidyl 3-kinase (PI3K), which is an intracellular central mediator of cell survival 
Figure 2. Significantly mutated genes in ESCC specimens. Top: number of synonymous and nonsynonymous 
mutations. Middle: significantly mutated genes coloured by mutation types. Left: Nonsilent mutation frequency 
of each gene. Right: significantly mutated genes ranked by q-value according to MutSigCV analysis.
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signals. AKT phosphorylates mTOR (mammalian target of rapamycin), downstream of PI3K, and PTEN inhibits 
AKT by dephosphorylation. In our study, in addition to finding the nonsense mutations in PTEN that could cause 
loss of function, we also detected hotspot mutations in the p110a domain (p.N345K, p.C420R, p.E545K, p.E542K) 
and C-terminal portion (p.H1047R, p.H1047L) coded by PIK3CA. These hotspot mutations were reported to 
induce a gain of function in Oncogenicity17.
In recent years, frequent mutations in the NFE2L2/KEAP1/CUL3 pathway had been reported in many types 
of cancers, including ESCC10,18–21. In our study, we identified mutations in NFE2L2 in 9.6% of the ESCC samples 
and mutations in KEAP1 and CUL3 in 2.9% of the ESCC samples. We found that the mutations in NFE2L2 were 
almost mutually exclusive with mutations in KEAP1 and CUL3 and that the mutations in KEAP1 and CUL3 were 
mutually exclusive (Supplementary Fig. 2B, Supplementary Table 7).
Histone modification enzymes control the chromatin structure and regulate gene expression22. Histone mod-
ifications play an important role in the occurrence and development of cancers. We identified two significantly 
mutated genes (KMT2D and KDM6A) associated with histone modification. KMT2D encoded histone methyl-
transferase, and promoted the transcriptional activation of target genes through modifying Histone H3 Lysine 4 
Figure 3. Analysis of AJUBA. (A) Somatic mutation types and positions on AJUBA. (B) Left: Kaplan-Meier 
survival curve for AJUBA was significantly associated with patient survival, p < 0.1 was considered statistically 
significant. Right: Cox proportional hazards model for patients, p < 0.05 was considered statistically significant. 
(C) Comparison of the expression of AJUBA in tumour and normal samples in the TCGA ESCC cohort. (D) 
Comparison of the expression of AJUBA in the AJUBA mutant and wild-type samples in the TCGA ESCC 
cohort.
www.nature.com/scientificreports/
5Scientific REPORtS | 7: 15324  | DOI:10.1038/s41598-017-14909-5
Trimethylation (H3K4me3)23. In our study, the nonsilent mutation frequency of KMT2D was 11%, and 30 muta-
tions (46.9%) were truncating (nonsense mutation and frame shift).
CNA Analysis of ESCC. In the CNA analysis, a total of 57 genomic regions were obtained using 31 WGS 
data, and 34 focused regions exhibited significant amplification or deletion (q < 0.05, Supplementary Table 8, 
Supplementary Fig. 4), including 11q13.3 amplification and 9p21.3 deletion, which have been reported to be 
associated with human cancers3,24.
We also conducted CNA analysis on 283 WES data, and selected the CNA genes that were recorded in the 
CGC database for further analysis. CGC is a database that includes genes with substantial published evidence in 
Oncology. We used this database to select the potentially functional CNA genes.
Hierarchical clustering analysis on the CNA of CGC genes revealed four subgroups within the study patients 
(Fig. 4A). Group3 and group4 showed a high frequency of CNAs, followed by group1. Patients in group2 exhib-
ited the fewest CNAs and were significantly associated with an early stage (Fisher’s exact test, p = 0.016) and fewer 
lymph node metastases (Fisher’s exact test, p = 0.005). Group3 was significantly associated with late stage (Fisher’s 
exact test, p = 0.038). We found that patients in group3 and group4 showed high similarity in the CNA spectrum. 
Thus, we combined the two groups as subtype3 for additional analysis. Accordingly, group1 and group2 were also 
renamed subtype1 and subtype2, respectively. By performing Kaplan-Meier analysis, we found that subtype3 
marked for worse prognosis compared with patients of subtype2 (p = 0.007, Log-rank test, Fig. 4B). Moreover, we 
performed Student’s t-test to select the most representative CNA genes between subtype3 and subtype2. Finally, 
128 genes were identified as significantly differential CNA genes between the two subtypes (q < 0.001, gain or loss 
frequency >= 40% in either subtype, Fig. 4C, Supplementary Table 9).
To further interpret the clinical significances of the representative CNA genes, we annotated the 128 CNA 
genes with the CIViC database25 (Supplementary Table 10). PIK3CA amplification was found in 15.7%(8 of 51) 
and 71.8%(89 of 124) cases in subtype2 and subtype3, respectively, which has been reported to be associated with 
sensitivity to several drugs in epithelial ovarian cancer, stomach carcinoma and head and neck squamous cell 
carcinoma26–28. FBXW7 deletion was found in 0%(0 of 51) and 46.8%(58 of 124) cases in subtype2 and subtype3, 
respectively, and has been reported to be associated with increased sensitivity of drugs in breast cancer and renal 
cell carcinoma29,30.
Immunogenomic analysis of ESCC. To find immunotherapy clues for ESCC, we comprehensively ana-
lysed the immune-related signalling pathways in ESCC. NF-kB is a protein complex that controls cell prolifer-
ation and survival and plays an important role in regulating the immune response to infection31. In this study, 
a total of 12 genes, including TRAF, IRAK, TAB2, TLR, IL1R, and MYD88, harboured nonsilent mutations, 
Figure 4. Characterization of ESCC subtypes. (A) Hierarchical clustering analysis on the CNA of cancer gene 
census (CGC). Upper bars: stage, lymphatic metastasis and vital status. Bottom bars: nonsilent mutations of 
each sample and number of CNA genes. The line represents the median number of CNA genes. (B) Kaplan-
Meier analysis comparing survival of patients stratified by subtype. (C) Multidimensional scaling screen for 
CGC genes by comparing subtypes 3 and 2. Genes that q < 0.001 and frequency of copy number gain or loss in 
subtypes 3 or 2 >= 40% were highlighted in red.
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indicating the activation of the NF-kB signalling pathway in tumour cells. The persistent activation of NF-kB can 
lead to cell resistance to apoptosis and resistance to chemotherapeutic drug-induced apoptosis. JAK-STAT is a 
signal transduction pathway that is stimulated by cytokines and is involved in cell proliferation, differentiation, 
apoptosis, immune regulation and many other important biological processes. JAK-STAT consists of three main 
components: tyrosine kinase-related receptors, tyrosine kinase JAK and transcription factor STAT32. Disrupted 
JAK-STAT functionality can result in immune deficiency syndromes and cancers32. We identified 18 mutated 
genes in this pathway, 13 of which belong to the three JAK-STAT components.
Discussion
In this study, we have gathered the published ESCC sequencing data and performed a comprehensive analy-
sis on the largest ESCC cohort currently available. By deciphering the mutational signatures from these 490 
ESCC tumours, we identified five mutational signatures. All these five signatures had been reported in ESCC 
before7,13,14. Notably, our survival analysis showed that signature4 was associated with poor survival in ESCC 
patients (Supplementary Fig. 2C). It was reported that this signature was characterized mainly by C > T mutations 
and was associated with defective DNA mismatch repair13.
To understand the dominant mutational signatures in individual patients, we performed a hierarchical clus-
tering based on the enrichment of specific mutational signatures and identified 3 subgroups of patients. Cluster1 
was dominated by signature3, Cluster2 was dominated by signatures 1 and 5, and Cluster3 was dominated by 
signature2. Notably, we found that Cluster3 indicated a better prognosis compared with Clusters 1 and 2.
Although the causes that may have led to the different survival time among the three ESCC groups remain 
largely unknown, our results provide an atlas of the molecular subtypes of ESCC with potential prognostic value 
based on the largest ESCC sample size to date.
Our study also presented a more comprehensive mutational landscape of ESCC. In addition to the 
well-defined ESCC-related genes, including TP53, AJUBA, CDKN2A, KMT2D(MLL2), NOTCH1, NOTCH3, 
PIK3CA, RB1, CREBBP, NFE2L2, ZNF750, FAT1, KDM6A, FBXW7, and TGFBR2, we identified three novel 
oesophageal cancer-related genes: PTEN, DCDC1 and CUL3.
PTEN was frequently mutated in other human cancers as an important tumour suppressor33, including breast, 
prostate, gastric cancer and endometrial carcinomas33–35. The protein encoded by PTEN preferentially dephos-
phorylates phosphoinositide substrates and inhibits integrin-mediated cell spreading and cell migration36. In 
this study, we identified 4 nonsense mutations in the phosphatase and C2 domain of PTEN. These nonsense 
mutations resulted in truncated proteins, indicating that they may have loss-of-function effects. CUL3 encodes 
a member of the cullin protein family, and the encoded protein was reported to form the core component of 
CUL3-based E3 ligase complex and to play a critical role in the poly-ubiquitination and subsequent degradation 
of NFE2L2 protein in lung squamous cell carcinoma37. We identified 10 somatic mutations in the Cullin domain 
that play an essential role in targeting proteins for ubiquitin-mediated degradation38. These results indicated that 
the mutations in CUL3 gene may affect the degradation of NFE2L2 protein in ESCC cells. DCDC1 was another 
novel SMG identified in our study, which encodes a member of the doublecortin family39. We observed frequent 
nonsilent mutations and deletion this gene, which may cause dysregulated microtubule polymerization and con-
tributes to ESCC development. An important finding here was that the mutations of AJUBA were significantly 
associated with prognosis (p = 0.026, log–rank test, Fig. 3B). Most of the mutations identified in AJUBA were 
stop-gain and frame shift mutations that occurred in the LIM domain and were predicted to truncate the protein 
(Fig. 3A), consistent with a recent report that the expression level of AJUBA tended to be lower in AJUBA-mutant 
tumours than in tumours with wild-type AJUBA4. However, AJUBA was reported to be a binding partner of 
large tumour suppressor type 2 (LATS2) and to inhibit the proliferation of tumour cells via Hippo signalling 
cascade40. Overexpression of AJUBA was also shown to increase the proliferation of head and neck squamous cell 
carcinoma (HNSCC) cells, and mutations in AJUBA were associated with the sensitivity of HNSCC to treatment 
with cell-cycle inhibitors41. More recently, another study showed that the AJUBA level was significantly higher in 
ESCC tissues compared with matched adjacent tissues. AJUBA functions as an oncogenic gene in both in vitro 
and in vivo experiments42.
In this study, we found that loss of functional mutations in AJUBA is associated with a better outcome of ESCC 
patient. This result was consistent with the oncogenic function of AJUBA in ESCC and highlighted the potential 
application of AJUBA as a prognostic marker in ESCC.
To further investigate the biological function of cancer-associated genes, we classified the SMGs into dif-
ferent categories according to previous functional studies. Our results showed that the signalling pathways are 
implicated in ESCC, including cell cycle and apoptosis regulation, histone modification, Wnt pathway, NOTCH 
pathway, PI3K/AKT pathway, P53 signalling pathway, and Hedgehog signalling pathway. PI3K-AKT is an impor-
tant signalling pathway that has been identified in human cancers and is involved in regulating cell functions 
such as proliferation, differentiation, apoptosis, and glucose transport43. Inactivation of this pathway was usually 
caused by mutations in key genes, such as gain-of-function mutations in PIK3CA and AKT, and loss of function 
mutations of PTEN. The detection of loss of function mutations in PTEN and gain of function mutations in 
PIK3CA in our study indicated different mechanisms of dysregulation of the PIK3CA/AKT pathway contrib-
uting to ESCC development. NFE2L2 is a transcriptional activator for genes in response to oxidative stress. In 
tumour cells, mutations of NFE2L2 were reported to increase resistance to oxidative stress, and promote tumour 
growth44. Notably, we also found that the mutations in NFE2L2, KEAP1, and CUL3 were almost mutually exclu-
sive (Supplementary Fig. 3C), which was consistent with the finding in SqCC and HNSCC19,20 and indicated that 
the mutation and dysfunction of the NFE2L2/KEAP1/CUL3 pathway may contribute to the development of ESCC 
by increasing the resistance to oxidative stress. Moreover, two significantly mutated genes (KMT2D and KDM6A) 
associated with histone modification were identified in our study. These findings have deepened our understand-
ing on the molecular mechanisms underlying the tumourigenesis of ESCC.
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Through immunogenomic analysis, we detected several key gene mutations in the immune pathway, and the 
effects of these mutations on the immune mechanisms need to be further studied.
By analysing potentially functional CNA genes (according to CGC) from the WES data and performing hier-
archical clustering analysis of these genes, we identified 4 ESCC subgroups with different CNA gene numbers and 
clinical relevance (Fig. 4). Notably, patients in group2 exhibited fewer CNAs and were significantly associated 
with early stages and fewer lymph node metastases. Group3 exhibited higher CNAs and was significantly asso-
ciated with late stages. These results suggest the links between the CNA background and tumour progression of 
ESCC and provide a novel genomic classification method that may help differentiate ESCC patients with dissim-
ilar tumour stages and metastasis statuses. As a result, different therapy strategies could be chosen accordingly.
Moreover, Kaplan-Meier analysis showed that the combination of group3 and group4 (subtype3) marked for 
worse patient prognosis compared with patients of group2 (subtype2). This result indicates that higher CNAs in 
the CGC genes are associated with poor patient prognosis and suggest the potential utility of CNA data of these 
CGC genes as prognostic marker in ESCC.
Given the differences of clinical features between subtype2 and subtype3, it is intriguing to identify the rep-
resentative CNA genes between these two subtypes, and to find potential therapeutic target for the patients in 
different subtypes. By comparing the CNA values in subtype3 and subtype2 and annotated the CNA genes with 
the CIViC database, we identified two high frequency CNA genes which had been associated with drug responses 
in different cancers by the former studies. Notably, high frequency amplification of PIK3CA gene was found in 
subtype3 (71.8%), however the amplification frequency of this gene in subtype2 was low (15.7%). And according 
to the annotation result of CIViC, we found that PIK3CA amplification was associated with partial response to 
treatment with PI3K inhibitor pictilisib (GDC-0941) in epithelial ovarian cancer patients26, and positively asso-
ciated with the sensitive of PI3K inhibitor in stomach carcinoma and head and neck squamous cell carcinoma 
(HNSCC)27,28. Given that the CNA spectrums was similar between ESCC and HNSCC3, our results suggest that 
PIK3CA amplification may also serve as a therapeutic target for PI3K inhibitor in ESCC. FBXW7 is another high 
frequency CNA gene associated with drug responses. We identified deletion of FBXW7 gene in 58/124 (46.8%) 
of patients in subtype3, but found no deletion of this gene in subtype2. And according to the annotation result of 
CIViC, we found that FBXW7 deletion enhanced the sensitivity to mTOR inhibitors in breast cancer and renal 
cell carcinoma29,30.
Although further clinical trials are still needed, the dramatically differences of FBXW7 deletion and PIK3CA 
amplification between the subtype2 and subtype3 in our ESCC cohort, suggested that mTOR inhibitors and PI3K 
inhibitors may also suit for certain groups of ESCC patient. And the molecular subtyping base on CNA data may 
be helpful to classify ESCC patients for different drugs. These analyses have shed some light into the potential 
application of the CNAs as therapeutic target in ESCC.
To sum up, we have performed a comprehensive genomic analysis on the largest ESCC cohort. We identified 
SMGs, mutational signatures, and subtypes of ESCC related to prognosis. We also identified potential therapeutic 
targets for special subtype of ESCC. Our analysis deepened our understanding of the heterogeneity of ESCC and 
shed light on the molecular mechanisms and pathways underlying ESCC. These studies may provide a potential 
improvement to the strategies that are used for the therapy and prognosis of ESCC patients.
Methods
Genome data collection and processing. We collected fastq or somatic mutations data of 492 paired 
ESCC samples from seven publications (Supplementary Table 1), consisting of 41 whole-genome sequences and 
451 whole-exome sequences. The clinical data were also acquired (Supplementary Table 2). Of the 492 cases 
of ESCC, the fastq data of 323 cases from 4 publications3,4,6,7 were re-analysed with our standard pipeline, and 
somatic mutations from the remaining publications were combined for further analysis. To improve the accuracy 
and comparability of the data, we eliminated one hyper-mutant sample and filtered the false positive mutations 
with our own panel of normal datasets and the Exome Aggregation Consortium (ExAC) database. Finally, 490 
cases were used for further analysis.
The Fastq data from 323 cases were processed according to the following pipeline. Low-quality reads with 
more than five unknown bases and sequencing adaptors were removed. The remaining high-quality reads were 
aligned to NCBI human reference (hg19) using BWA45. Picard (http://broadinstitute.github.io/picard/) was used 
to mark duplicates, and Genome Analysis Toolkit46 (v.1.0.6076, GATK IndelRealigner) to improve the accuracy of 
the genome alignment. Somatic point mutations were detected using muTect47. Somatic Indels were detected with 
GATK Somatic Indel Detector. The somatic variations combined the remaining publications’ somatic mutations 
were annotated with Oncotator48.
To further enhance the accuracy of somatic mutations, we filtered the false positive mutations with a thresh-
old of greater than 5% of mutation frequency in normal samples according to our panel of normal bams, and a 
threshold of greater than 1% in the Exome Aggregation Consortium (ExAC) database.
Copy number alterations (CNAs) were first detected with SegSeq for 31 WGS, and GATK4 Alpha for 283 
WES. GISTIC2.049 was performed to identify significantly amplified or deleted genomic regions. Hierarchical 
clustering was used to identify sample subtypes. Student’s two-sided t-test was used to select significant differen-
tial CNAs between subtype3 and subtype2. P values were adjusted using the R package ‘p.adjust’, and q < 0.001 
was defined as statistically significant. We employed CIViC25 to identify CNA genes associated response a targeted 
therapy.
Mutational signature analysis. The mutational signatures were displayed using a 96-context classification. 
A nonnegative matrix factorization (NMF) was used to identify the operative processes based upon the reproduc-
ibility of the signatures and low error for reconstructing the original catalogues.
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Identification of significantly mutated genes. Significantly mutated genes (SMGs) were detected using 
MuSigCV (mutation significance with covariates), which identifies genes highly relevant to cancer rather than 
high frequency mutations by considering the background mutation events. A gene was considered to be a SMG if 
it satisfied the condition for statistical significance (q < 0.1) at MuSigCV.
Analysis of clinical pathological data. The survival rate was calculated by the Kaplan-Meier method, and 
the difference was compared by the Log-rank method. Cox proportional hazards model was used for the analysis 
of hazards, as implemented in the R package ‘survival’ (http://cran.r-project.org/web/ packages/survival/). We 
removed the patients whose survival information were unavailable. By univariate analyses, the significance of the 
clinical variables was p < 0.1 level. Multivariate analyses were performed using age, gender, pathological grade, N, 
and stage as covariates, and the significance of clinical multivariates was p < 0.05.
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